Overview
Tarpeyo is approved by the U.S. Food and Drug Administration (FDA) to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Tarpeyo is also known by its drug name, budesonide.

Tarpeyo is a corticosteroid designed to release its medication in the ileum (part of the small intestine), where it targets immune-related inflammation that contributes to kidney damage in IgAN. By reducing this inflammation, Tarpeyo helps protect kidney function over time.

How do I take it?
Prescribing information states that Tarpeyo is taken as an oral delayed-release capsule once daily in the morning, at least one hour before a meal. The typical treatment duration is nine months. In the last two weeks of treatment, the dose is typically reduced. Tarpeyo should be swallowed whole and not opened, crushed, or chewed. It should be taken exactly as prescribed by a healthcare provider.
Side effects

Common side effects of Tarpeyo include peripheral edema (swelling in the limbs), hypertension (high blood pressure), muscle spasms, acne, headache, upper respiratory tract infection, facial swelling, weight gain, indigestion, skin rash, joint pain, and increased white blood cell count.

Rare but serious side effects may include hypercorticism (excess steroid hormone levels), suppression of the adrenal gland’s hormone production, and increased risk of infections. People with liver disease may have a higher risk of these effects. Tarpeyo can also worsen conditions like diabetes and high blood pressure, and may reduce the effectiveness of vaccines.

For more information about this treatment, visit:

Tarpeyo (Budesonide) Delayed Release Capsules, for Oral Use — Calliditas Therapeutics